Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05624879

Accelerated Resolution Therapy for Early Maladaptive Grief

The purpose study is to test the effects of accelerated resolution therapy (ART) on pre-loss grief and prolonged grief disorder among older adult family caregivers (FCGs). Additionally, to better understand predictors of response to ART, and cognitive processes that occur among grieving individuals following ART.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

60 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Mayo Clinic Arizona, Phoenix, Arizona, United States

Loading trial locations.

About this study

Accelerated Resolution Therapy (ART) is an evidence-based treatment for post-traumatic distress in civilians and veterans that may be useful in alleviating maladaptive grief prior to bereavement and could prevent prolonged grief disorder following bereavement. Researchers are proposing to test the efficacy of ART, a low-risk, brief therapy with a strong theoretical rationale for treatment success in maladaptive grief and supported by the promising results of a recently completed preliminary trial. Additional aims of the study are to examine changes in cognitive appraisal and integration of loss following ART using a mixed methods approach and to evaluate personal, social, and psychological factors predictors of response.

During the proposed double blinded, randomized, controlled two arm clinical trial, older adult family caregivers will receive either ART or an educational program that is matched for time and attention. Each participant will receive four sessions of either the ART intervention or the control intervention. Data collection will occur at screening/enrollment (T1), at the end of the 4-session intervention period (T2) and at 6-months (T3) and 13-months post bereavement (T4). A subgroup of 20 participants randomly assigned to ART will participate in semi-structured interviews to enhance understanding of cognitive appraisal and integration of loss.

This trial will provide critical information on the efficacy of the ART intervention as a potential first-line treatment option for pre-loss grief and preventative option for prolonged grief disorder, and contribute new information about characteristics of individuals most likely to benefit from ART.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Primary caregiver of immediate family member who has a life expectancy of less than 12 months
  • Score of 30 or higher on the PG-12-R, indicating clinically significant pre-loss grief
  • Denial of suicidal ideation or intent, with no evidence of psychotic behavior.

Exclusion criteria

  • Since becoming a family caregiver (FCG), they have engaged in another trauma based psychotherapeutic regimen (EMDR, prolonged exposure therapy, trauma focused cognitive behavioral therapy) that could influence response to accelerated resolution therapy (ART).
  • Self-reported or clinically assessed major psychiatric disorder (e.g., bipolar disorder, schizophrenia).
  • Score of > 2 on the adapted CAGE questionnaire indicating alcohol /drug dependence.
  • Cognitive impairment (SPMSQ > 4 errors).

Treatment and study plan

Accelerated Resolution Therapy

Behavioral

A brief psychotherapeutic intervention delivered by trained therapists in a maximum of 4 sessions. Sessions will focus on providing relief from the distress related to an anticipated loss and to shift focus from distress and loss back to the relationship.

Other names: ART

Information and Support

Other

4 sessions of a standardized social work intervention. Standard of care including education and active listening.

Primary outcomes

  1. Changes in pre-loss grief

    Time frame: Baseline, 4 weeks

    Measured by 14-item self-reported Prolonged Grief-12-Revised (PG-12-R) designed to measure the grief experience of current family caregivers of persons living with progressive disease. Total grief level scores greater than or equal to 30 indicate high levels of pre-loss grief.

  2. Changes in prolonged grief disorder

    Time frame: 6 and 13 months post-bereavement

    Measured by 13-item self-reported Prolonged Grief-13-Revised (PG-13-R) designed to assess indicators of pathological grief. Total scores range from 10-50; with score >29 = prolonged grief.

  3. Changes in clinical measure of prolonged grief disorder

    Time frame: 6 and 13 months post-bereavement

    Measured by 31-item Structured Clinical Interview for Prolonged Grief Disorder (SCI-P) administered by healthcare professional. Higher scores = higher complicated grief symptoms.

Other outcomes

  1. Change in depression

    Time frame: Baseline, 4 weeks, 6 and 13 months post-bereavement

    Measured using the self-reported 9-item Personal Health Questionnaire (PHQ-9) to assess how often subjects have been bother about specific problems in the last 2 weeks. Total scores range from 0-27; with score >9 = depression.

  2. Caregiver burden

    Time frame: Baseline

    Measured using the self-reported 4-item Caregiver Role Overload questionnaire. Individual statement agreement on scale of "completely" agree to "not at all". Higher responses indicate more burden.

  3. Change in perceived stress

    Time frame: Baseline, 6 and 13 months post-bereavement

    Measured using the self-reported 10-item NIH toolbox Item Bank/Fixed Form v2.0 - Perceived Stress questionnaire. Score range from 26-34; with higher score indicating worse stress.

  4. Change in physical and mental health

    Time frame: Baseline, 6 and 13 months post-bereavement

    Measured using the self-reported 10-item Patient-Reported Outcomes Measurement Information System (PROMIS)-Global Health questionnaire. Total score range 0-20; with higher scores indicate better health.

  5. Pessimism

    Time frame: Baseline

    Measured using the self-reported 10-item Revised Life Orientation Test (LOT-R). Total score range from 0-40, with higher scores indicating more optimistic

  6. Change in life stressors

    Time frame: Baseline, 6 and 13 months post-bereavement

    Measured using the self-reported 13-item Social Readjustment Rating Scale where subjects indicate Yes or No and frequency of events that have occurred or expected to occur.

  7. Change in trauma symptoms

    Time frame: Baseline, 4 weeks, 6 and 13 months post-bereavement

    Measured using the self-reported 20 item PTSD Checklist for DSM-5 (PCL-5) assess subjects response to very stressful experiences within the past week. Score range from 0-80; with cut-point for PTSD of 33.

  8. Change in social support

    Time frame: Baseline, 4 weeks, 6 and 13 months post-bereavement

    Measured using the self-reported 8-item NIH toolbox Item Bank v2.0 - Emotional Support questionnaire. Score range from 8-40; with higher score indicating better emotional support.

  9. Change in anxiety

    Time frame: Baseline, 4 weeks, 6 and 13 months post-bereavement

    Measured using the self-reported 7-item Generalized Anxiety Disorder Scale (GAD-7) to assess anxiety symptoms is the last week. Total score range from 0-2; with score >9 = high anxiety

Study contacts

Contact information is provided by the study sponsor or research team.

Katharine E Sheffield, MA, CCRP

CONTACT

[email protected]

904-953-3972

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Collaborators

  • National Institute on Aging (NIA)

Registry information

Official study title

Accelerated Resolution Therapy for Early Maladaptive Grief: A Clinical Trial

Important dates

Study start
2023
Primary completion
2028
Study completion
2028
First posted
Nov 22, 2022
Registry last updated
Sep 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.